Verrica Pharmaceuticals reports Q3 EPS (54c), consensus (36c)

Reports Q3 revenue $2.917M, consensus $510,000. “Following the U.S Food and Drug Administration approval of YCANTH for the treatment of molluscum in July, we continue to build momentum across our commercial operations,” said Ted White, Verrica’s President and Chief Executive Officer. “As the only FDA-approved product for the treatment of molluscum, we are seeing broad awareness and interest in prescribing YCANTH across dermatology and pediatric practices. With our commercial and reimbursement teams fully in place, we are focused on executing our launch strategy and expanding our coverage among commercial plans and managed Medicaid plans. To date, over 112 million lives have access to YCANTH(TM) through commercial insurance or managed Medicaid plans, and YCANTH has already gained acceptance of fee-for-service Medicaid coverage in Connecticut, Arkansas, New Jersey and Nevada. “